The report will be delivered in 2-3 business days.

Arthritis Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change

Starting Price : $ 4000.00 $3200.00 | Pages : 150 | Published : October 2020 | SKU CODE : 7722 | Format :


The arthritis monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of arthritis diseases. Arthritis is referred to as the joint pain that is characterized by inflammation, tenderness, pain and stiffness in and around the joints. Different monoclonal antibody drugs are used for the treatment of arthritis. These include infliximab, adalimumab and golimumab. The market consists of revenue generated by the companies manufacturing monoclonal antibody drugs for arthritis by the sales of these products.

The global arthritis monoclonal antibodies market is expected to decline from $46.48 billion in 2019 to $45.18 billion in 2020 at a compound annual growth rate (CAGR) of -2.8%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $56.05 billion in 2023 at a CAGR of 7.45%.

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Centre for Disease Control and Prevention (CDC), in 2015, the adult percentage of arthritis ranges from 11.2% to 42.7%, which varies by country and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1% and the worldwide estimates of osteoarthritis include 9.6% men and 18% women. The increased prevalence of arthritis and thee demand for personalized medicine is increasing the demand for the arthritis monoclonal antibody market.

The high cost of monoclonal antibodies is expected to hamper the global arthritis monoclonal antibody market. According to the American Journal of Managed Care (AJMC), a survey was conducted to know the average price of monoclonal antibodies approved in the last 20 years by the FDA across disease states and found that the average annual price of 1-year treatment for each monoclonal antibody indication was $96,731. The high costs of these antibodies are basically due to the cost incurred in development and production. High costs of monoclonal antibodies are therefore expected to limit the market growth.

The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target specific and has good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

In May 2020, AbbVie acquired Allergan for $63 billion. AbbVie is a global biopharmaceutical company, whose key therapeutic areas include Immunology and Neuroscience. It is now significantly expanding its revenue base and maintaining its position in immunology by acquiring Allergan. Allergan is a global pharmaceutical leader that manufactures devices, biologics, surgical and regenerative medicinal products all across the world.

The major players covered in the global arthritis monoclonal antibodies market are  Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC, Mylan N.V, Bristol Myers Squibb, Eli Lily and Company, Thermofischer Scientific, Sanofi, Novo Nordisk A/S, Daiichi Sankyo Company ltd., Seattle genetics, Teva pharmaceutical industries, Shanghi Junsi bioscience ltd, GenScript, Sigma-Aldrich Co. LLC, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, Celgene, Celldex Therapeutics.

The countries covered in the global arthritis monoclonal antibodies market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The regions covered in the global arthritis monoclonal antibodies market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global arthritis monoclonal antibodies market is segmented - 1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima. 2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Others.

    1. Executive Summary

    2. Arthritis Monoclonal Antibodies (mabs) Market Characteristics

    3. Arthritis Monoclonal Antibodies (mabs) Market Size And Growth

    3.1. Global Arthritis Monoclonal Antibodies (mabs) Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Arthritis Monoclonal Antibodies (mabs) Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Arthritis Monoclonal Antibodies (mabs) Market Segmentation

    4.1. Global Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Remicade

    Humira

    Enbrel

    Rituxan

    Orencia

    Actemra

    Simponi

    Cimzia

    Remsima

    4.2. Global Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Rheumatoid Arthritis

    Osteoarthritis

    Psoriatic Arthritis

    Ankylosing Spondylitis

    Fibromyalgia

    Others

    5. Arthritis Monoclonal Antibodies (mabs) Market Regional And Country Analysis

    5.1. Global Arthritis Monoclonal Antibodies (mabs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Arthritis Monoclonal Antibodies (mabs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Arthritis Monoclonal Antibodies (mabs) Market

    6.1. Asia-Pacific Arthritis Monoclonal Antibodies (mabs) Market Overview

    6.2. Asia-Pacific Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Arthritis Monoclonal Antibodies (mabs) Market

    7.1. China Arthritis Monoclonal Antibodies (mabs) Market Overview

    7.2. China Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    7.3. China Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Arthritis Monoclonal Antibodies (mabs) Market

    8.1. India Arthritis Monoclonal Antibodies (mabs) Market Overview

    8.2. India Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    8.3. India Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Arthritis Monoclonal Antibodies (mabs) Market

    9.1. Japan Arthritis Monoclonal Antibodies (mabs) Market Overview

    9.2. Japan Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9.3. Japan Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Arthritis Monoclonal Antibodies (mabs) Market

    10.1. Australia Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10.2. Australia Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Arthritis Monoclonal Antibodies (mabs) Market

    11.1. Indonesia Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11.2. Indonesia Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Arthritis Monoclonal Antibodies (mabs) Market

    12.1. South Korea Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12.2. South Korea Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Arthritis Monoclonal Antibodies (mabs) Market

    13.1. Western Europe Arthritis Monoclonal Antibodies (mabs) Market Overview

    13.2. Western Europe Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13.3. Western Europe Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Arthritis Monoclonal Antibodies (mabs) Market

    14.1. UK Arthritis Monoclonal Antibodies (mabs) Market Overview

    14.2. UK Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14.3. UK Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Arthritis Monoclonal Antibodies (mabs) Market

    15.1. Germany Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15.2. Germany Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Arthritis Monoclonal Antibodies (mabs) Market

    16.4. France Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16.5. France Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Arthritis Monoclonal Antibodies (mabs) Market

    17.1. Eastern Europe Arthritis Monoclonal Antibodies (mabs) Market Overview

    17.2. Eastern Europe Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Arthritis Monoclonal Antibodies (mabs) Market

    18.1. Russia Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18.2. Russia Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Arthritis Monoclonal Antibodies (mabs) Market

    19.1. North America Arthritis Monoclonal Antibodies (mabs) Market Overview

    19.2. North America Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19.3. North America Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Arthritis Monoclonal Antibodies (mabs) Market

    20.1. USA Arthritis Monoclonal Antibodies (mabs) Market Overview

    20.2. USA Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20.3. USA Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Arthritis Monoclonal Antibodies (mabs) Market

    21.1. South America Arthritis Monoclonal Antibodies (mabs) Market Overview

    21.2. South America Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21.3. South America Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Arthritis Monoclonal Antibodies (mabs) Market

    22.1. Brazil Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22.2. Brazil Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Arthritis Monoclonal Antibodies (mabs) Market

    23.1. Middle East Arthritis Monoclonal Antibodies (mabs) Market Overview

    23.2. Middle East Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23.3. Middle East Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Arthritis Monoclonal Antibodies (mabs) Market

    24.1. Africa Arthritis Monoclonal Antibodies (mabs) Market Overview

    24.2. Africa Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24.3. Africa Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Arthritis Monoclonal Antibodies (mabs) Market Competitive Landscape And Company Profiles

    25.1. Arthritis Monoclonal Antibodies (mabs) Market Competitive Landscape

    25.2. Arthritis Monoclonal Antibodies (mabs) Market Company Profiles

    25.2.1. Johnson & Johnson

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Roche

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Novartis

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Pfizer Inc

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. AbbVie Inc.

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Arthritis Monoclonal Antibodies (mabs) Market

    27. Arthritis Monoclonal Antibodies (mabs) Market Trends And Strategies

    28. Arthritis Monoclonal Antibodies (mabs) Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Arthritis Monoclonal Antibodies (mabs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Arthritis Monoclonal Antibodies (mabs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: China, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: China, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: India, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: India, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: Japan, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Japan, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: Australia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Australia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: Indonesia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Indonesia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: South Korea, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: South Korea, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: Western Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: Western Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: UK, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: UK, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Germany, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Germany, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 27: France, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 28: France, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 29: Eastern Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 31: Russia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 32: Russia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 33: North America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 34: North America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 35: USA, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 36: USA, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 37: South America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 38: South America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 39: Brazil, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 40: Brazil, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 41: Middle East, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 42: Middle East, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 43: Africa, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 44: Africa, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 45: Johnson & Johnson Financial Performance
  • Table 46: Roche Financial Performance
  • Table 47: Novartis Financial Performance
  • Table 48: Pfizer Inc Financial Performance
  • Table 49: AbbVie Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Arthritis Monoclonal Antibodies (mabs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Arthritis Monoclonal Antibodies (mabs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: China, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: China, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: India, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: India, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: Japan, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Japan, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: Australia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Australia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: Indonesia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: South Korea, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: South Korea, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: Western Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: UK, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: UK, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Germany, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Germany, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 27: France, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 28: France, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 29: Eastern Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 31: Russia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 32: Russia, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 33: North America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 34: North America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 35: USA, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 36: USA, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 37: South America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 38: South America, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 39: Brazil, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 40: Brazil, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 41: Middle East, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 42: Middle East, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 43: Africa, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 44: Africa, Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 45: Johnson & Johnson Financial Performance
  • Figure 46: Roche Financial Performance
  • Figure 47: Novartis Financial Performance
  • Figure 48: Pfizer Inc Financial Performance
  • Figure 49: AbbVie Inc. Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)